Drugs / Runimotamab
Runimotamab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03448042 | Jun 2018 → Nov 2027 expected | cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Runimotamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03448042 ↗ |
| Known as | BTRC-4017A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650458 ↗ |
| Known as | RG-6194 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650458 ↗ |
| Known as | RO-7227780 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650458 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650458 ↗ |
| Route | Intravenous | “Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.” NCT03448042 ↗ |